3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase 3
7
Phase 1
4
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
57
Carcinoma, Non-Small-Cell Lung
46
Ovarian Neoplasms
31
Stomach Neoplasms
22
Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
18
Lung Neoplasms
18
Neoplasm Metastasis
17
Fallopian Tube Neoplasms
14
Triple Negative Breast Neoplasms
13
Esophageal Neoplasms
13
Esophageal Squamous Cell Carcinoma
10
Colorectal Neoplasms
9
Carcinoma, Ovarian Epithelial
9
Melanoma
8
Head and Neck Neoplasms
8
Endometrial Neoplasms
8
Uterine Cervical Neoplasms
6
Pancreatic Neoplasms
6
Carcinoma, Renal Cell
6
Adenocarcinoma of Lung
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Advanced Solid Tumors
5
Testicular Neoplasms
4
Testicular Germ Cell Tumor
4
Recurrence
4
Carcinoma, Transitional Cell
4
Interventions
tremelimumab
1
poly(I).poly(c12,U)
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
genexol-PM
1
abagovomab
1
Topotecan
1
Paclitaxel
1
Oxaliplatin
1
MOC31PE immunotoxin
1
LY-2157299
1
Introns
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Drug Therapy
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Celecoxib
1
Capecitabine
1
Bevacizumab
1
AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase
1
Acids
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Peritoneal Neoplasms
×
Paclitaxel
×
Clear all
NCT03618758
2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2
Completed
35 enrolled